Months after Amgen's landmark KRAS approval, Chris Varma bags a crossover round for next-gen candidate
For years, mutant, cancer-fueling KRAS proteins were considered “undruggable.” That all changed in May, when Amgen’s KRAS-blocking drug Lumakras snagged the FDA’s first approval in the field. And now a slate of investors are betting $88.5 million on a Bay Area startup’s next-generation candidate.
Frontier Medicines has closed a hefty Series B round, co-led by Woodline Partners and RA Capital Management, the company said on Monday. Deerfield Management, Deep Track Capital, ArrowMark Partners, Driehaus Capital Management, Sphera Healthcare, DCVC’s Bio fund, Droia Ventures and MPM Capital also chimed in. With the latest round, it’s possible CEO Chris Varma has an IPO on the mind.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.